Novo Nordisk Receives a Hold from Credit Suisse

By Jason Carr

Credit Suisse analyst Rebekah Harper reiterated a Hold rating on Novo Nordisk (NYSE: NVO) on November 29. The company’s shares closed yesterday at $33.60, close to its 52-week low of $30.89.

According to TipRanks.com, Harper is ranked #3092 out of 4243 analysts.

Novo Nordisk has an analyst consensus of Hold.

Based on Novo Nordisk’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $4.14 billion and quarterly net profit of $1.47 billion. In comparison, last year the company earned revenue of $4 billion and had a net profit of $1.25 billion.

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas. The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.